Dec
7
Big Pharms & HGH
December 7, 2009 | Leave a Comment
Pharmaceutical companies are awakening to the fact that being first in market and first in class is no longer enough. While most agree that the blockbuster approach is all but dead, there is considerable debate about its successor. “Big pharma†continues to invest record amounts in drug discovery research, but what can they learn from specialty pharma, drug delivery devices companies, and even the generics industry? A select group of thought leaders from pharma, biopharma, device manufacturers, payers, providers, and policymakers met recently at an industry forum event sponsored by Cambridge Consultants to address these issues and answer the question: “What will the shape of the drug delivery landscape look like ten years from now and what drivers would create this change?â€
   Formulation can help to mitigate systemic impact, and some opportunities are thought to exist where formulation and device development are progressing hand-in-hand. In the case of the Glide Pharma (Oxford, UK) Glide-SDI, solid doses of the drug are injected via a reusable actuator eliminating the use of needles. Where injection delivery is used, optimizing compliance and comfort is the key driver. It is anticipated that micro-electronics will add some significant value to such devices by offering dose reminders, dose recording, and compliance monitoring. An example of this is EasyPod, where a sophisticated device has had a significant impact in the human growth hormone market, improving acceptance, compliance and market share for Merck Serono (Geneva, Switzerland). Incorporating these advanced delivery devices are not without challenge.
How about a safe alternative to this injectible HGH drug? We found it! Click here. Read the entire HGH article.
   Formulation can help to mitigate systemic impact, and some opportunities are thought to exist where formulation and device development are progressing hand-in-hand. In the case of the Glide Pharma (Oxford, UK) Glide-SDI, solid doses of the drug are injected via a reusable actuator eliminating the use of needles. Where injection delivery is used, optimizing compliance and comfort is the key driver. It is anticipated that micro-electronics will add some significant value to such devices by offering dose reminders, dose recording, and compliance monitoring. An example of this is EasyPod, where a sophisticated device has had a significant impact in the human growth hormone market, improving acceptance, compliance and market share for Merck Serono (Geneva, Switzerland). Incorporating these advanced delivery devices are not without challenge.
How about a safe alternative to this injectible HGH drug? We found it! Click here.
Dec
10
Former Pfizer (HGH) VP Now Wants In Obama Administration
December 10, 2008 | Leave a Comment
Pfizer whistleblower and compulsive blogger Peter Rost has tossed his Panama hat into the ring for the post of FDA commissioner in the new Obama administration.
He’s got the “backing†— or at least the paperwork — of Sen. Sherrod Brown and Rep. Jo Ann Emerson. Rost is best-known as the former Pfizer vp who dragged the company’s name through the mud by opposing its position on reimportation and by going public with the news that Pfizer acquired a company it knew was selling human growth hormone(hgh) illegally.
Read about a safe, legal hgh product used my many and recommended by a doctor: click here!
Read the entire Pfizer/HGH article
Oct
17
China Pharmaceutical Company Expanding For More HGH Production
October 17, 2008 | Leave a Comment
GeneScience Pharmaceuticals Co., Ltd. (GenSci), one of China’s leading biopharmaceuticals producers (including hgh), recently started the construction of its new medicine of genetic engineering base in the Changchun High-tech Industrial Development Area, Jilin Province, Northeast China.
In the near future, this base will be created as the nation’s largest and most profitable genetic engineering pharmacy center with ten pillar products, including recombinant human growth hormone (hgh), thymosin, and follicle stimulating hormone. Its sales revenue is likely to reach CNY 2 billion to CNY 5 billion within the following five to eight years, said insiders.
Want to learn more about a safe alternative to real hgh? Click here.
Recommended Links
GET YOUR FREE HGH &
ANTI-AGING REPORT!
- Get your own FREE copy of the groundbreaking report, "Seven Age Reversing Secrets" – packed with valuable tips and tricks to help you fight the aging process and have the highest quality of life possible!